NCT05870579 2025-08-21
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
Novartis
Phase 1 Recruiting
Clinical Trials
5 trialsNCT02626507 2022-02-09
Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer
Hoffman Oncology
Phase 1 Unknown
NCT02586675 2022-01-21
TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT01149356 2015-05-25
RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 1 Terminated
NCT01240928 2013-08-20
MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 1 Withdrawn